Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S D Voss

Showing results (21-30 of 30) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 30 results.
Cancer Immunology, Immunotherapy : CII|January 1, 1989
Serum levels of the low-affinity interleukin-2 receptor molecule (TAC) during IL-2 therapy reflect systemic lymphoid mass activationS D Voss, J A Hank, C A Nobis, et al.
Medical Image Computing and Computer-Assisted Intervention : MICCAI ... International Conference on Medical Image Computing and Computer-Assisted Intervention|January 5, 2013
Reliable assessment of perfusivity and diffusivity from diffusion imaging of the bodyM Freiman, S D Voss, R V Mulkern, et al.
The Journal of Experimental Medicine|October 1, 1990
Increased expression of the interleukin 2 (IL-2) receptor beta chain (p70) on CD56+ natural killer cells after in vivo IL-2 therapy: p70 expression does not alone predict the level of intermediate affinity IL-2 bindingS D Voss, R J Robb, G Weil-Hillman, et al.
Blood|December 15, 1995
Distinction between gamma c detection and function in YT lymphoid cells and in the granulocyte-macrophage colony-stimulating factor-responsive human myeloid cell line, Tf-1N L Farner, S D Voss, T P Leary, et al.
Journal of Immunotherapy : Official Journal of the Society for Biological Therapy|February 1, 1992
Serum CD25 levels during interleukin-2 therapy: dose dependence and correlations with clinical toxicity and lymphocyte surface sCD25 expressionM P Bogner, S D Voss, R Bechhofer, et al.
Cancer Research|May 1, 1990
Natural killer cells activated by interleukin 2 treatment in vivo respond to interleukin 2 primarily through the p75 receptor and maintain the p55 (TAC) negative phenotypeG Weil-Hillman, S D Voss, P Fisch, et al.
Science (New York, N.Y.)|November 30, 1990
Recognition by human V gamma 9/V delta 2 T cells of a GroEL homolog on Daudi Burkitt's lymphoma cellsP Fisch, M Malkovsky, S Kovats, et al.
Cancer Research|March 15, 1991
Biological and clinical effects of intravenous tumor necrosis factor-alpha administered three times weeklyJ H Schiller, B E Storer, P L Witt, et al.
Cancer|January 15, 1992
Clinical and biologic effects of combination therapy with gamma-interferon and tumor necrosis factorJ H Schiller, P L Witt, B Storer, et al.
Journal of Immunology (Baltimore, Md. : 1950)|September 22, 1998
Cloning of BY55, a novel Ig superfamily member expressed on NK cells, CTL, and intestinal intraepithelial lymphocytesA Anumanthan, A Bensussan, L Boumsell, et al.
Pageof 3

Showing results (21-30 of 30) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 30 results.
Cancer Immunology, Immunotherapy : CII|January 1, 1989
Serum levels of the low-affinity interleukin-2 receptor molecule (TAC) during IL-2 therapy reflect systemic lymphoid mass activationS D Voss, J A Hank, C A Nobis, et al.
Medical Image Computing and Computer-Assisted Intervention : MICCAI ... International Conference on Medical Image Computing and Computer-Assisted Intervention|January 5, 2013
Reliable assessment of perfusivity and diffusivity from diffusion imaging of the bodyM Freiman, S D Voss, R V Mulkern, et al.
The Journal of Experimental Medicine|October 1, 1990
Increased expression of the interleukin 2 (IL-2) receptor beta chain (p70) on CD56+ natural killer cells after in vivo IL-2 therapy: p70 expression does not alone predict the level of intermediate affinity IL-2 bindingS D Voss, R J Robb, G Weil-Hillman, et al.
Blood|December 15, 1995
Distinction between gamma c detection and function in YT lymphoid cells and in the granulocyte-macrophage colony-stimulating factor-responsive human myeloid cell line, Tf-1N L Farner, S D Voss, T P Leary, et al.
Journal of Immunotherapy : Official Journal of the Society for Biological Therapy|February 1, 1992
Serum CD25 levels during interleukin-2 therapy: dose dependence and correlations with clinical toxicity and lymphocyte surface sCD25 expressionM P Bogner, S D Voss, R Bechhofer, et al.
Cancer Research|May 1, 1990
Natural killer cells activated by interleukin 2 treatment in vivo respond to interleukin 2 primarily through the p75 receptor and maintain the p55 (TAC) negative phenotypeG Weil-Hillman, S D Voss, P Fisch, et al.
Science (New York, N.Y.)|November 30, 1990
Recognition by human V gamma 9/V delta 2 T cells of a GroEL homolog on Daudi Burkitt's lymphoma cellsP Fisch, M Malkovsky, S Kovats, et al.
Cancer Research|March 15, 1991
Biological and clinical effects of intravenous tumor necrosis factor-alpha administered three times weeklyJ H Schiller, B E Storer, P L Witt, et al.
Cancer|January 15, 1992
Clinical and biologic effects of combination therapy with gamma-interferon and tumor necrosis factorJ H Schiller, P L Witt, B Storer, et al.
Journal of Immunology (Baltimore, Md. : 1950)|September 22, 1998
Cloning of BY55, a novel Ig superfamily member expressed on NK cells, CTL, and intestinal intraepithelial lymphocytesA Anumanthan, A Bensussan, L Boumsell, et al.
Pageof 3